Celldex Therapeutics, Inc.
CLDXUS売上高
$2M
百万USD
営業利益
$-287M
百万USD
純利益
$-259M
百万USD
ROE
-49.1%
最新FY
EPS
$-3.90
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $1M | - | - |
| FY2021 | Q2 | $3M | - | - |
| FY2021 | Q3 | $0M | - | - |
| FY2021 | FY | $5M | - | $-1.64 |
| FY2022 | Q1 | $0M | - | $-0.49 |
| FY2022 | Q2 | $0M | - | $-0.77 |
| FY2022 | Q3 | $0M | - | $-0.57 |
| FY2022 | FY | $2M | - | $-2.40 |
| FY2023 | Q1 | $1M | - | $-0.62 |
| FY2023 | Q2 | $0M | - | $-0.65 |
| FY2023 | Q3 | $2M | - | $-0.81 |
| FY2023 | FY | $7M | - | $-2.92 |
| FY2024 | Q1 | $0M | - | $-0.56 |
| FY2024 | Q2 | $2M | - | $-0.54 |
| FY2024 | Q3 | $3M | - | $-0.64 |
| FY2024 | FY | $7M | - | $-2.45 |
| FY2025 | Q1 | $1M | - | $-0.81 |
| FY2025 | Q2 | $1M | $-57M | $-0.85 |
| FY2025 | Q3 | $3M | $-67M | $-1.01 |
| FY2025 | FY | $2M | $-259M | $-3.90 |
| FY2026 | Q1 | $0M | $-79M | $-1.18 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $10M | $4M | $7M | $5M | $2M | $7M | $7M | $2M |
| 営業利益 | $-133M | $-122M | $-156M | $-55M | $-63M | $-71M | $-115M | $-155M | $-195M | $-287M |
| 純利益 | - | - | - | - | - | - | - | - | - | $-259M |
| 総資産 | $383M | $316M | $156M | $123M | $236M | $445M | $353M | $466M | $792M | $583M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $265M | $236M | $124M | $94M | $209M | $419M | $326M | $429M | $747M | $527M |
| 営業CF | - | $-100M | $-75M | $-46M | $-40M | $-61M | $-104M | $-107M | $-158M | $-211M |
| EPS | - | - | - | - | - | $-1.64 | $-2.40 | $-2.92 | $-2.45 | $-3.90 |
| BPS | $2.15 | $1.68 | $9.97 | $5.35 | $5.28 | $8.98 | $6.91 | $7.68 | $11.25 | $7.92 |
| ROE | - | - | - | - | - | - | - | - | - | -49.1% |